Drugs / PF-08046044
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06254495 | May 2024 → Apr 2026 | anaplastic large cell lymphoma, classic Hodgkin lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified | Pfizer | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-08046044 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06254495 ↗ |
| Known as | SGN-35C | “A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers” NCT06254495 ↗ |
| Route | Intravenous | “Given into the vein (IV; intravenously)” NCT06254495 ↗ |